Profile: Kevin Garey

Kevin Garey
Kevin W. Garey, Pharm.D., M.S., FASHP
Chair, Department of Clinical Sciences & Administration
Professor of Pharmacy Practice
Department of Clinical Sciences and Administration
Texas Medical Center Campus, Room 322
1441 Moursund Street
Houston, TX 77030
832-842-8386
832-842-8383 (Fax)

KGarey@uh.edu

Education

Bachelor of Science in Pharmacy, 1991-95, Dalhousie University, Halifax, Nova Scotia

Doctorate of Pharmacy, 1995-97, University at Buffalo, Buffalo, NY

M.S. in Biometry, 2007, University of Texas School of Public Health, Houston, TX

Research Interests

  • Infectious disease epidemiology
  • Post-operative infections
  • Biofilm activity of antimicrobials
  • Clostridium difficile infection

Awards & Honors

  • Impact Paper of the Year, Society of Infectious Diseases Pharmacists, 2012 ("A randomized, double-blind, placebo-controlled pilot study to assess the ability of rifaximin to prevent recurrent diarrhoea in patients with Clostridium difficile infection." J Antimicrob Chemother. 2011 Dec;66(12):2850-5. PubMed abstract)
  • Fellow, American Society of Health-System Pharmacists, 2012
  • Faculty Research Excellence Award, UH College of Pharmacy, 2007
  • Society of Infectious Diseases Pharmacists Impact Paper in Infectious Diseases, 2007
  • Literature Award in Drug Therapy, American Society of Health-System Pharmacists Research & Education Foundation, 2007
  • Pharmacotherapy Paper of the Year Award, Society of Infectious Diseases Pharmacists, 2007
  • UH College of Pharmacy Rho Chi Teacher Excellence Award, 2003
  • UH College of Pharmacy Faculty Teaching Excellence Award, 2003
  • Rho Chi member, 2003
  • Who's Who in Medicine and Healthcare, 2003

Courses

  • Third year: Therapeutics, OTC
  • Electives: Infectious diseases I and II, Drug literature evaluation, research study designs
  • Graduate: Pharmacoepidemiology

Selected Publications

Patel TS, Crutchley RD, Tucker AM, Cottreau J, Garey KW. Crofelemer for the treatment of chronic diarrhea in patients living with HIV/AIDS. HIV AIDS (Auckl). 2013 Jul 15;5:153-62. doi: 10.2147/HIV.S30948. Print 2013. PMID: 23888120

Jardin CG, Palmer HR, Shah DN, Le F, Beyda ND, Jiang Z, Garey KW.  Assessment of treatment patterns and patient outcomes before vs after implementation of a severity-based Clostridium difficile infection treatment policy. J Hosp Infect. 2013 Sep;85(1):28-32. doi: 10.1016/j.jhin.2013.04.017. Epub 2013 Jul 5.

Yeo QM, Crutchley R, Cottreau J, Tucker A, Garey KW. Crofelemer, a novel antisecretory agent approved for the treatment of HIV-associated diarrhea. Drugs Today (Barc). 2013 Apr;49(4):239-52. doi: 10.1358/dot.2013.49.4.1947253.PMID: 23616951 

Huang JS, Jiang ZD, Garey KW, Lasco T, Dupont HL. Use of rifamycin drugs and development of infection by rifamycin-resistant strains of Clostridium difficile. Antimicrob Agents Chemother. 2013 Jun;57(6):2690-3. doi: 10.1128/AAC.00548-13. Epub 2013 Apr 1. PMID: 23545528

Shah DN, Bhatt NS, Welch JK, Koo HL, Garey KW. Defining acute renal dysfunction as a criterion for the severity of Clostridium difficile infection in patients with community-onset vs hospital-onset infection. J Hosp Infect. 2013 Apr;83(4):294-9. doi: 10.1016/j.jhin.2012.12.011. Epub 2013 Feb 20. PMID: 23433867 

Natali BJ, Varkey AC, Garey KW, Liebl M. Impact of a pharmacotherapy alerting system on medication errors. Am J Health Syst Pharm. 2013 Jan 1;70(1):48-52. doi: 10.2146/ajhp120126. PMID: 23261900 

Jiang ZD, Hoang LN, Lasco TM, Garey KW, Dupont HL. Physician attitudes toward the use of fecal transplantation for recurrent Clostridium difficile infection in a metropolitan area. Clin Infect Dis. 2013 Apr;56(7):1059-60. doi: 10.1093/cid/cis1025. Epub 2012 Dec 7. PMID: 23223589 

Haines LA, Putney KS, Varkey DA, Frost C, Pitman EP, Aparasu RR, Garey KW. Pilot of a patient-centered pharmacy practice model. Am J Health Syst Pharm. 2012 Nov 1;69(21):1860-1. doi: 10.2146/ajhp120132. PMID: 23111668 

Beyda ND, Chuang SH, Alam MJ, Shah DN, Ng TM, McCaskey L, Garey KW. Treatment of Candida famata bloodstream infections: case series and review of the literature. J Antimicrob Chemother. 2013 Feb;68(2):438-43. doi: 10.1093/jac/dks388. Epub 2012 Oct 19. Review. PMID: 23085777

Beyda ND, Lewis RE, Garey KW. Echinocandin Resistance in Candida Species: Mechanisms of Reduced Susceptibility and Therapeutic Approaches (July/August). Ann Pharmacother. 2012 Jul-Aug;46(7-8):1086-96. doi: 10.1345/aph.1R020. Epub 2012 Jul 17. Review.

Singh V, Arora V, Alam MJ, Garey KW. Inhibition of biofilm formation by esomeprazole in Pseudomonas aeruginosa and Staphylococcus aureus. Antimicrob Agents Chemother. 2012 Aug;56(8):4360-4. doi: 10.1128/AAC.00544-12. Epub 2012 Jun 4. PMID: 22664967

Tran TT, Palmer HR, Weston J, Hirsch EB, Shah DN, Cottreau J, Tam VH, Garey KW. Evaluation of a daptomycin dose-optimization protocol. Am J Health Syst Pharm. 2012 Jun 1;69(11):979-84.PMID: 22610031

Shah DN, Yau R, Lasco TM, Weston J, Salazar M, Palmer HR, Garey KW. Impact of prior inappropriate fluconazole dosing on isolation of fluconazole-nonsusceptible Candida species in hospitalized patients with candidemia. Antimicrob Agents Chemother. 2012 Jun;56(6):3239-43. Epub 2012 Mar 12. PMID: 22411611

Le F, Arora V, Shah DN, Salazar M, Palmer HR, Garey KW. A real-world evaluation of oral vancomycin for severe Clostridium difficile infection: implications for antibiotic stewardship programs. Pharmacotherapy. 2012 Feb;32(2):129-34. doi: 10.1002/PHAR.1002. Epub 2012 Jan 24. PMID: 22392421

Santimaleeworagun W, Wongpoowarak P, Chayakul P, Pattharachayakul S, Tansakul P, Garey KW. In vitro activity of colistin or sulbactam in combination with fosfomycin or imipenem against clinical isolates of carbapenem-resistant Acinetobacter baumannii producing OXA-23 carbapenemases. Southeast Asian J Trop Med Public Health. 2011 Jul;42(4):890-900.

Cottreau J, Tucker A, Crutchley R, Garey KW. Crofelemer for the treatment of secretory diarrhea. Expert Rev Gastroenterol Hepatol. 2012 Jan;6(1):17-23. Epub 2011 Nov 3.

Garey KW, Ghantoji SS, Shah DN, Habib M, Arora V, Jiang ZD, Dupont HL. A randomized, double-blind, placebo-controlled pilot study to assess the ability of rifaximin to prevent recurrent diarrhoea in patients with Clostridium difficile infection. J Antimicrob Chemother. 2011 Dec;66(12):2850-5.

Palmer HR, Weston J, Gentry L, Salazar M, Putney K, Frost C, Tipton JA, Cottreau J, Tam VH, Garey KW. Improving patient care through implementation of an antimicrobial stewardship program. Am J Health Syst Pharm. 2011 Nov 15;68(22):2170-4.

Mora AL, Salazar M, Pablo-Caeiro J, Frost CP, Yadav Y, Dupont HL, Garey KW. Moderate to High Use of Opioid Analgesics Are Associated With an Increased Risk of Clostridium difficile Infection. Am J Med Sci. 2012 Apr;343(4):277-80.

Crutchley RD, Gathe J, Mayberry C, Trieu A, Abughosh S, Garey KW. Risk Factors for Vitamin D Deficiency in HIV-Infected Patients in the South Central United States. AIDS Res Hum Retroviruses. 2012 May;28(5):454-9. Epub 2011 Oct 19.

Shah DN, Yau R, Weston J, Lasco TM, Salazar M, Palmer HR, Garey KW. Evaluation of antifungal therapy in patients with candidaemia based on susceptibility testing results: implications for antimicrobial stewardship programmes. J Antimicrob Chemother. 2011 Sep;66(9):2146-51.

Arora V, Kachroo S, Ghantoji SS, Dupont HL, Garey KW. High Horn's index score predicts poor outcomes in patients with Clostridium difficile infection. J Hosp Infect. 2011 Sep;79(1):23-6.

S Sethi, KW Garey, V Arora, S Ghantoji, P Rowan, M Smolensky, HL DuPont. Increased rate of irritable bowel syndrome and functional gastrointestinal disorders after Clostridium difficile Infection. J Hosp Infect 2011;77:172-3

Santimaleeworagun W, Wongpoowarak P, Chayakul P, Pattharachayakul S, Tansakul P, Garey KW. Clinical outcomes of patients infected with carbapenem-resistant Acinetobacter baumannii treated with single or combination antibiotic therapy. J Med Assoc Thai. 2011 Jul;94(7):863-70.

Halton K, Arora V, Singh V, Ghantoji SS, Shah DN, Garey KW. Bacterial colonization on writing pens touched by healthcare professionals and hospitalized patients with and without cleaning the pen with alcohol-based hand sanitizing agent. Clin Microbiol Infect. 2011 Jun;17(6):868-9. doi: 10.1111/j.1469-0691.2011.03494.x.

Koo HL, Garey KW, Dupont HL. Future novel therapeutic agents for Clostridium difficile infection. Expert Opin Investig Drugs. 2010 Jul;19(7):825-36. Review.

Garey KW, Jiang ZD, Ghantoji S, Tam VH, Arora V, DuPont HL. A common polymorphism in the interleukin-8 gene promoter is associated with increased risk for recurrent Clostridium difficile infection. Clin Infect Dis 2010; 51(12): 1406-10

Bhagunde P, Chang KT, Singh R, Singh V, Garey KW, Nikolaou M, Tam VH. Mathematical modeling to characterize the inoculum effect. Antimicrob Agents Chemother. 2010 Nov;54(11):4739-43.

Dupont HL, Garey KW. Clostridium difficile infection: an emerging epidemic with more questions than answers. Future Microbiol. 2010 Aug;5(8):1153-6.

Palmer HR, Cottreau JM, Garey KW, Hirsch EB, Musick WL, Tam VH, Yeh RF; Houston Infectious Diseases Network. Significant publications on infectious diseases pharmacotherapy in 2009. Am J Health Syst Pharm. 2010 Aug;67(15):e34-42. Review.

Cottreau J, Baker SF, DuPont HL, Garey KW. Rifaximin: a nonsystemic rifamycin antibiotic for gastrointestinal infections. Expert Rev Anti Infect Ther. 2010 Jul;8(7):747-60.

Tam VH, Rogers CA, Chang KT, Weston JS, Caeiro JP, Garey KW. Impact of multidrug-resistant Pseudomonas aeruginosa bacteremia on patient outcomes. Antimicrob Agents Chemother. 2010 Sep;54(9):3717-22.

Shah D, Dang MD, Hasbun R, Koo HL, Jiang ZD, DuPont HL, Garey KW. Clostridium difficile infection: update on emerging antibiotic treatment options and antibiotic resistance. Expert Rev Anti Infect Ther. 2010 May;8(5):555-64. Review.

Crutchley RD, Miller J, Garey KW. Crofelemer, a novel agent for treatment of secretory diarrhea. Ann Pharmacother. 2010 May;44(5):878-84.

Jiang ZD, DuPont HL, La Rocco M, Garey KW. In vitro susceptibility of Clostridium difficile to rifaximin and rifampin in 359 consecutive isolates at a university hospital in Houston, Texas. J Clin Pathol. 2010 Apr;63(4):355-8.

Ghantoji SS, Sail K, Lairson DR, DuPont HL, Garey KW. Economic healthcare costs of Clostridium difficile infection: a systematic review. J Hosp Infect. 2010 Apr;74(4):309-18. Review

Birtcher KK, Corbett SM, Pass SE, Coyle EA, Yeh RF, Tipton J, Garey KW; Academic Pharmacy Symposium. Symposium on roles of and cooperation between academic- and practice-based pharmacy clinicians. Am J Health Syst Pharm. 2010 Feb 1;67(3):231-8.

Tam VH, Chang KT, Abdelraouf K, Brioso CG, Ameka M, McCaskey LA, Weston JS, Caeiro JP, Garey KW. Prevalence, resistance mechanisms, and susceptibility of multidrug-resistant bloodstream isolates of Pseudomonas aeruginosa. Antimicrob Agents Chemother. 2010 Mar;54(3):1160-4.

Salazar M, Baskin L, Garey KW, DuPont HL. Clostridium difficile-related death rates in Texas 1999-2005. J Infect. 2009 Nov;59(5):303-7.

Salazar M, Garey KW, Jiang ZD, Dao-Tran T, Dupont H. Changing Clostridium difficile infection testing and treatment trends at a large tertiary care teaching hospital. Pharm World Sci. 2009 Oct;31(5):565-71.

Y Yadav, KW Garey, TK Dao-Tran, V Kaila, KY Elhor Gbito, and H. DuPont. An Automated System to Identify Clostridium difficile Infection Among Hospitalized Patients. J Hosp Infect 2009 Aug; 72 (4):337-41

VH Tam, KT Chang, AN Schilling, MT LaRocco, LO Genty, KW Garey. Impact of AmpC over-expression on outcomes of patients with Pseudomonas aeruginosa bacteremia.  Diag Micro Infect Dis 2009 Mar;63(3):279-85

Garey KW, Jiang ZD, Bellard A, Dupont HL. Rifaximin in treatment of recurrent Clostridium difficile-associated diarrhea: an uncontrolled pilot study. J Clin Gastroenterol. 2009 Jan;43(1):91-3

Garey KW, Vo QP, Lewis RE, Saengcharoen W, LaRocco MT, Tam VH. Increased bacterial adherence and biomass in Pseudomonas aeruginosa bacteria exposed to clarithromycin. Diagn Microbiol Infect Dis. 2009 Jan;63(1):81-6.

Garey KW, Vo QP, Larocco MT, Gentry LO, Tam VH. Prevalence of type III secretion protein exoenzymes and antimicrobial susceptibility patterns from bloodstream isolates of patients with Pseudomonas aeruginosa bacteremia. J Chemother. 2008 Dec;20(6):714-20.

Garey KW, Sethi S, Yadav Y, DuPont HL. Meta-analysis to assess risk factors for recurrent Clostridium difficile infection. J Hosp Infect. 2008 Dec;70(4):298-304.

Yeh RF, Kuper KM, Coyle EA, Garey KW, Ikwuagwu JO, Maclayton DO, Mohr JF, Musick WL, Pass SE, Rios E, Tam VH; Houston Infectious Disease Network. Significant publications on infectious diseases pharmacotherapy in 2007. Am J Health Syst Pharm. 2008 Nov 15;65(22):e72-9

Garey KW, Martorell MV, Vo QP, Tam VH. Killing activity of rifampin with piperacillin therapy against adherent cells of Pseumodomas aeruginosa. J Chemother. 2008 Oct;20(5):652-4.

Garey KW, Dao-Tran TK, Jiang ZD, Price MP, Gentry LO, Dupont HL. A clinical risk index for Clostridium difficile infection in hospitalised patients receiving broad-spectrum antibiotics. J Hosp Infect. 2008 Oct;70(2):142-7.

Garey KW, Jiang ZD, Yadav Y, Mullins B, Wong K, Dupont HL. Peripartum Clostridium difficile infection: case series and review of the literature. Am J Obstet Gynecol. 2008 Oct;199(4):332-7. Review.

Garey KW, Salazar M, Shah D, Rodrigue R, DuPont HL. Rifamycin antibiotics for treatment of Clostridium difficile-associated diarrhea. Ann Pharmacother. 2008 Jun;42(6):827-35. Review.

Garey KW, Amrutkar P, Dao-Tran TK, Frost CP, Chen H, Essien EJ, Gentry LO. Economic benefit of appropriate timing of vancomycin prophylaxis in patients undergoing cardiovascular surgery. Pharmacotherapy. 2008 Jun;28(6):699-706.

Garey KW, Lai D, Dao-Tran TK, Gentry LO, Hwang LY, Davis BR. Interrupted time series analysis of vancomycin compared to cefuroxime for surgical prophylaxis in patients undergoing cardiac surgery. Antimicrob Agents Chemother. 2008 Feb;52(2):446-51.

Lim TP, Garey KW, Tam VH. Pharmacokinetic/Pharmacodynamic antimicrobial individualization and optimization strategies. Curr Infect Dis Rep. 2008 Mar;10(1):9-13.

Tam VH, Gamez EA, Weston JS, Gerard LN, Larocco MT, Caeiro JP, Gentry LO, Garey KW. Outcomes of bacteremia due to Pseudomonas aeruginosa with reduced susceptibility to piperacillin-tazobactam: implications on the appropriateness of the resistance breakpoint. Clin Infect Dis. 2008 Mar 15;46(6):862-7.

Presentations & Abstracts

Garey KW, Shah DN, Habib M, Lasco T. Clinical assessment of nanotechnology and miniaturized magnetic resonance to detect candidemia in hospitalized patients. IDSA 49th Annual Meeting, Boston, MA. October 20-23, 2011.

Grimes CZ, Shah DN, Koo HL, DuPont HL, Garey KW. Validity of recommended criteria for attributable mortality associated with Clostridium difficile Infection. IDSA 49th Annual Meeting, Boston, MA. October 20-23, 2011.

Shah DN, Dima-ala A, Dolormente K, Arora V, Garey KW. Incidence of antibiotic-associated diarrhea in hospitalized patients given broad spectrum antibiotics. 51st ICAAC, Chicago, IL. Sept. 17-20, 2011.

Shah DN, Koo HL, Lasco TM, Palmer HR, Garey KW. Assessment of attributable mortality rate of candidemia in candidemia pts with inpatient mortality. 51st ICAAC, Chicago, IL. Sept. 17-20, 2011.

D Shah, R Yau, J Weston, T Lasco, M Salazar, H Palmer, KW Garey. Pre-exposure to antifungals as a risk factor for fluconazole-non-susceptible Candida species in hospitalized patients with candidemia. 21st ECCMID / 27th ICC meeting, Milan, Italy. May 7-10, 2011

KW Garey, S Ghantoji, D Shah, M Habib, V Arora, ZD Jiang, H DuPont. A randomised, double-blind, placebo-controlled pilot study to assess the effect of rifaximin “chaser” to prevent recurrent diarrhoea in patients with Clostridium difficile infection. 21st ECCMID / 27th ICC meeting, Milan, Italy. May 7-10, 2011

W Santimaleeworagun, J Christensen, V Singh, DN Shah, KT Chang, VH Tam, and KW Garey. Molecular epidemiology of Clostridium difficile and prevalence of the NAP-1strain among patients admitted to a general and a private hospital in Houston, Texas USA. 21st ECCMID / 27th ICC meeting, Milan, Italy. May 7-10, 2011

Xu R, Salazar M, Weston JS, Shah DN, Putney KS, Garey KW. Susceptibility of Candida species in patients with candidemia. SCCM’s 40th Critical Care Congress, San Diego, CA. January 16-18, 2011.

De La Cabada J, Jiang ZD, Ghantoji SS, Garey KW, Lasco TM, Larocco M, Shah D, DuPont HL. Fecal lactoferrin in Clostridium difficile infection as a predictor of single bouts vs. recurrent disease (Podium presentation). IDSA 48th Annual Meeting, Vancouver, Canada. October 21-24, 2010

Tran TC, Palmer HR, Weston JS, Hirsch EB, Shah DN, Cottreau JM, Tam VH, Garey KW. Daptomycin dose-effect relationship against vancomycin-resistant enterococcal bacteremia. ACCP 2010 Annual Meeting, Austin, TX. October 17-20, 2010.

Gordon SM, Shah DN, Tran TC, Lasco T, Garey KW. Variations in time to blood culture positivity stratified by Candida species and fluconazole susceptibility. ACCP 2010 Annual Meeting, Austin, TX. October 17-20, 2010. (Oral)

Shah DN, Yau RW, Weston J, Lasco T, Salazar M, Palmer H, Garey KW. Utility of fluconazole as de-escalation therapy in patients with fluconazole-susceptible candidemia. ACCP 2010 Annual Meeting, Austin, TX. October 17-20, 2010.

Tran TC, Palmer HR, Weston JS, Hirsch EB, Shah DN, Cottreau JM, Tam VH, Garey KW. Evaluation of daptomycin PK/PD dose optimization protocol. 50th ICAAC, Boston MA. Sept. 12-15, 2010. (Oral)

Shah DN, Yau RW, Weston J, Xu R, Salazar M, Palmer H, Garey KW. Changes to empiric antifungal therapy based on susceptibility testing results. 50th ICAAC, Boston MA. Sept. 12-15, 2010.

KW Garey, ZD Jiang, S Ghantoji, VH Tam, V Arora, and HL DuPont. A Common Polymorphism in the IL-8 Gene is Associated with Increased Risk for Recurrent Clostridium difficile Infection (Podium presentation). 49th ICAAC. San Francisco, CA. Sept. 14, 2009

F Le, KW Garey, M Salazar, SS Ghantoji, V Arora, VH Tam, and HL DuPont. Treatment of Clostridium difficile infection based on severity of illness. 49th ICAAC. San Francisco, CA. Sept. 12-15, 2009

V Arora, SS Ghantoji, N Ordonez, M Habib, R Hasbun, HL DuPont, and KW Garey. Risk factors for Mortality in Patients with Clostridium difficile Infection. 49th ICAAC. San Francisco, CA. Sept. 12-15, 2009

V Singh and KW Garey. Antimicrobial effects of esomeprazole against nosocomial biofilm producing organisms. 109th ASM Annual Meeting. Philadelphia, PA. May 17-21, 2009

TC Nguyen, V Singh, K Ledesma, VH Tam, KW Garey. Antibiotic synergy against biofilm-embedded methicillin-resistant Staphylococcus aureus with reduced susceptibility to vancomycin. 109th ASM Annual Meeting. Philadelphia, PA. May 17-21, 2009

Mora A, Salazar M, DuPont HL, and Garey KW. Narcotics as a Risk Factor for Clostridium difficile Infection (Podium presentation). 48th ICAAC/46th IDSA Annual Meeting, Washington DC, October 28, 2008

KW Garey, TK Dao-Tran, D Davies, LO Gentry. An “Antibiotic Time-out Protocol” significantly improves antibiotic prophylaxis timing in cardiovascular surgery patients. 47th ICAAC. Chicago, IL. September 2007

KW Garey, TK Dao-Tran, A Bellard, G Graham, ZD Jiang, MP Price, HL DuPont. A clinical risk index for Clostridium difficile associated diarrhea (CDAD) in hospitalized patients. 47th ICAAC. Chicago, IL. September 2007

KJ Suda, KW Garey, C Bertram, LH Danziger. A Population Based Analysis to Assess the Incidence of Clostridium difficile-associated diarrhea in the USA. 47th ICAAC. Chicago, IL. September 2007 (Podium presentation)

P Amrutkar, T Dao, C Frost, LO Gentry, H Chen, JE Essien, and KW Garey. Economic Benefit of Appropriate Antibiotic Timing in Patients Undergoing Cardiovascular Surgery. 46th ICAAC. San Francisco, CA. September 2006 (Latebreaker accepted abstract)

VH Tam, KT Chang, MT LaRocco, AN Schilling, K Poole, KW Garey. Prevalence and Mechanisms of Carbapenem Resistance in Bloodstream Isolates of Pseudomonas Aeruginosa. 46th ICAAC. San Francisco, CA. September 2006

Invited Presentations

Guideline and Literature Update in Infectious Diseases 2011 (Moderator and Presenter). ASHP Midyear Clinical Meeting, New Orleans LA. Dec. 7, 2011

Update on Fidaxomcin. Annual Meeting of the Society of Infectious Diseases Pharmacist. Chicago, IL. September 16, 2011

Preventing Health Care-Associated Infections. APhA Annual Meeting. Seattle, WA. March 28, 2011

Germ Nation: Infectious Disease Update 2010 (Encore), APhA Live. Memphis, TN. October 16, 2010

Infectious Diseases Update in Texas: From Bench to Bedside to Beyond (Moderator and presenter). 62th Annual Meeting of the Texas Society of Health System Pharmacists (TSHP), Galveston, TX. April 9, 2010

Germ nation: Infectious Disease Update. APhA Annual Meeting. Washington, DC. March 14, 2010

In case you missed it: Top Papers in Medicine, 2009 (Moderator and presenter). ASHP Midyear Clinical Meeting, Las Vegas, NV. Dec 8, 2009

Keeping up with the Guidelines: Infectious Diseases Guidelines (Moderator and presenter). ASHP Midyear Clinical Meeting, Las Vegas, NV. Dec 8, 2009

Most Influential Publications in Infectious Diseases Pharmacotherapy, 2008-2009. 49th ICAAC. San Francisco, CA. September 11 2009

Clinical Update for Managers (Moderator). ASHP Summer Meeting. Rosemont, IL. June 14-17, 2009

Don’t Bug Me! Ramping Up an Antimicrobial Stewardship Program (Moderator and presenter). ASHP Summer Meeting. Rosemont, IL. June 14-17, 2009

C. difficile update. University of Houston College of Pharmacy Infectious Disease Pharmacotherapy Symposium 2009, Houston, TX. May 1, 2009

Bugs vs. Drugs: Infectious Disease Update. APhA Annual Meeting. San Antonio, TX. April 3, 2009

In case you missed it: Top Papers in Medicine, 2008 (Moderator and presenter). ASHP Midyear Clinical Meeting. Orlando, FL. December 10, 2008

Why You Buggin? ID Update for the Frontline Pharmacist. ASHP's Great eXpectations Conference for New Practitioners 2008. New York, NY. August 22-24, 2008

Top Ten Papers in Infectious Diseases. 32nd Annual Symposium on Rational Therapeutics: A Seminar in General Medicine. Anaheim, CA. July 13, 2008

Optimal empiric therapy for candidemia. 5th Annual Critical Care Pharmacotherapy Symposium. Boston, MA. April 4th 2008

Update on Treatment of Fungal Infections in the Critically Ill Patient. Society of Critical Care Medicine Pharmacotherapy in Critical Illness, Philadelphia, PA. March 28-29, 2008

Prevention and Treatment Strategies for Clostridium difficile-associated Diarrhea. Society of Critical Care Medicine Pharmacotherapy in Critical Illness, Philadelphia, PA. March 28-29, 2008

Debates in Therapeutics: Should vancomycin be considered first line therapy for Clostridium difficile infections? ASHP Midyear Clinical Meeting. Las Vegas, NV. December 5, 2007

In case you missed it: Top Ten Papers in Medicine, 2007 (Moderator and presenter). ASHP Midyear Clinical Meeting. Las Vegas, NV. December 5, 2007

An update on Clostridium difficile. Arizona Pharmacy Alliance Health Systems Academy Conference. Phoenix, AZ. April 14, 2007

Hot Topics in Infectious Diseases (Co-moderator and presenter): Hypervirulent Clostridium difficile. 2006 ASHP Midyear Clinical Meeting. Anaheim, CA. December 7, 2006

Methicillin-resistant S. aureus. A treatment option debate. American College of Clinical Pharmacy New York State Chapter Annual Meeting. Albany, NY. October 6, 2006

Infectious disease update and Bacterial resistance. Infectious Disease Pharmacotherapy Symposium, Lee Garden Plaza Hotel, Hat-Yai, Songkla, Thailand. May 1-5 2006

Infectious Disease. 58th Annual Meeting of the Texas Society of Health-System Pharmacists (TSHP), Galveston, TX. April 2, 2006

Professional Service & Affiliations

  • American College of Clinical Pharmacy
  • American Society of Health-System Pharmacists
  • Society of Infectious Diseases Pharmacists
  • American Society of Microbiology
  • American Thoracic Society
  • Alliance for the Prudent Use of Antibiotics
  • Immunocompromised Host Society